SCHEDULING STATUS

S1

1. NAME OF THE MEDICINE

AMOROLFINE 5 % GLENMARK nail lacquer

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

AMOROLFINE 5 % GLENMARK: Each mL contains 50 mg amorolfine (as amorolfine hydrochloride).

For full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Liquid.

AMOROLFINE 5 % GLENMARK: Clear, colourless to pale yellow liquid.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

AMOROLFINE 5 % GLENMARK is indicated for onychomycoses caused by dermatophytes, yeasts and moulds. Only little experience is available in cases where the nail matrix was involved.

4.2 Posology and method of administration

Posology:

Onychomycoses

Nail Lacquer: To be applied to affected finger or toenails once or twice weekly.

Method of administration

Topical

The patient should apply the nail lacquer as follows:

1. Before the first application of **AMOROLFINE 5 % GLENMARK**, it is essential that the affected areas of nail (particularly the nail surfaces) should be filed down as thoroughly as possible using a disposable nail file supplied. The surface of the nail should then be cleansed and degreased using an alcohol-soaked swab (as supplied).
   Before repeating application of **AMOROLFINE 5 % GLENMARK**, the affected nails should be filed down again as required and must always first be cleansed with an alcohol-soaked swab to remove any remaining lacquer.
   Caution: Nail files used for affected nails must not be used for healthy nails.

2. With the applicator supplied, apply the nail lacquer to the entire surface of the affected nails and allow it to dry for approximately 3-5 minutes. For each nail to be treated, dip the applicator into the nail lacquer without wiping off any of the lacquer on the bottle neck.
   After use, clean the applicator with the same pre-soaked swab used before for nail cleansing. **Keep the bottle tightly closed.**

3. When working with organic solvents (thinners, white spirit, etc.) wear impermeable gloves to protect the **AMOROLFINE 5 % GLENMARK** on the nails. Treatment should be continued without interruption until the nail is regenerated and the affected areas are finally cured. The required duration of treatment depends essentially on intensity and localisation of the infection and on growth rate of the nails, but in general, it is six months for fingernails and nine to twelve months for toenails.
   Clinical experience indicates that cure is achieved after six months in approximately 50 % of distal onychomycosis cases in which less than 80 % of the nail surface was affected. Mycological cure was achieved in 60-80 % of cases.

4.3 Contraindications

AMOROLFINE 5 % GLENMARK is contra-indicated in:

- Individuals with known hypersensitivity to amorolfine hydrochloride or any of the excipients listed in section 6.1. These individuals should not reuse **AMOROLFINE 5 % GLENMARK**
- Pregnancy and lactation. No experience exists with pregnancy and breastfeeding while using **AMOROLFINE 5 % GLENMARK**
- Children.

4.4 Special warnings and precautions for use

AMOROLFINE 5 % GLENMARK should not be applied on the skin around the nail. Avoid contact of the lacquer with eyes, ears and mucous membranes.

Owing to the lack of clinical experience available to date, children (particularly young children and infants) should not be treated with **AMOROLFINE 5 % GLENMARK**.

Before repeat application of **AMOROLFINE 5 % GLENMARK**, cosmetic nail lacquer should be removed carefully. Use of cosmetic lacquers or artificial nails should be avoided during treatment with **AMOROLFINE 5 % GLENMARK**. After applying **AMOROLFINE 5 % GLENMARK**, an interval of at least 10 min should be respected before application of any cosmetic nail lacquer.

When organic solvents are used impermeable gloves shall be used otherwise **AMOROLFINE 5 % GLENMARK** will be removed.

A systemic or local allergic reaction could possibly occur after use of this product. If this happens, the product should be stopped immediately, and medical advice should be sought.
Remove the product carefully by using a nail remover solution.
The product should not be reapplied.

4.5 Interaction with other medicines and other forms of interaction

No interaction studies have been performed.

Use of nail varnish or artificial nails should be avoided during treatment

4.6 Fertility, pregnancy and lactation

Pregnancy

Experience with amorolfine use during pregnancy and/or lactation is limited. Only a few cases of exposure to topical amorolfine use in pregnant women have been reported in the post-authorisation setting, therefore the potential risk is unknown. Studies in animals have shown reproductive toxicity at high oral doses; it is unknown whether amorolfine is excreted in human milk. Amorolfine should not be used during pregnancy and/ or lactation unless clearly necessary.

4.7 Effects on ability to drive and use machines

AMOROLFINE 5 % GLENMARK has no influence on the ability to drive and use machines.

4.8 Undesirable effects

Nail disorders (e.g., nail discoloration, broken nails, brittle nails) may occur. These reactions can also be linked to the onychomycosis itself.

Tabulated summary of adverse reactions

The adverse reactions are listed by system organ class and absolute frequency.

System Organ Class	**Adverse Reactions**	**Frequency Category**
Immune system disorders	Hypersensitivity (systemic allergic reaction)	Frequency unknown

Skin and subcutaneous tissue disorders	Nail disorder, nail discolouration, onychoclasis (broken nails), onychorrhexis (brittle nails). However, these reactions can also be linked to the onychomycosis itself.	Frequent
	Skin burning sensation, contact dermatitis	Less frequent
	Erythema, pruritis, urticaria, blister	Frequency unknown

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Health care providers are asked to report any suspected adverse reactions to SAHPRA via the "**6.04 Adverse Drug Reactions Reporting Form**", found online under SAHPRA's publications:

https://www.sahpra.org.za/Publications/Index/8

4.9 Overdose

No systemic signs of overdose are expected following topical application of **AMOROLFINE 5 % GLENMARK.** Should **AMOROLFINE 5 % GLENMARK** be ingested, treatment should be symptomatic and supportive.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacological classification: A 13.9.2 Fungicides

AMOROLFINE 5 % GLENMARK is a topical antimycotic. Amorolfine has both *in vitro* fungicidal and fungistatic properties based on an alteration of the fungal cell membrane targeted primarily

on sterol biosynthesis. The ergosterol content is reduced, and at the same time unusual sterically nonplanar sterols accumulate.

Amorolfine has a broad spectrum of action *in vitro* against:

yeasts:	**Candida, Malassezia* or *Pityrosporum, Cryptococcus*
dermatophytes:	**Trichophyton*, **Microsporum*, **Epidermophyton*
moulds:	**Hendersonula*, **Alternaria*, **Scopulariopsis*, *Scytalidium*
dematiacea:	**Cladosporium*, *Fonsecaea*, *Wangiella* [* in onychomycosis]
dimorphic fungi:	*Coccidioides immites*, *Histoplasma capsulatum*, *Sporothrix schenckil*

In oral studies at high doses in animals, Amorolfine showed some additive effect *in vitro* and *in vivo* with several antifungals, including ketoconazole, itraconazole, terbinafine and griseofulvin, against dermatophytes. With the exception of Actinomyces, bacteria are not sensitive to amorolfine. *Propionbacterium acnes* is only slightly sensitive.

5.2 Pharmacokinetic properties

Absorption

Amorolfine from the nail lacquer penetrates and diffuses through the nail plate and effective concentrations accumulate in the nail bed where access to fungi is critical. Systemic absorption of the active ingredient is very low with this type of application.

Distribution

Following prolonged topical use of amorolfine nail lacquer there is no indication of accumulation in the body.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Absolute Alcohol (Ethanol 99 % v/v), ammonio methacrylate copolymer (type A), ethyl acetate, n-butyl acetate extra pure, triacetin (glycerol triacetate).

6.2 Incompatibilities

Not applicable

6.3 Shelf life

24 months

6.4 Special precautions for storage

Store at or below 25 °C.

Keep the bottle away from heat.

Keep the bottle tightly closed after use.

KEEP OUT OF THE REACH OF CHILDREN.

6.5 Nature and contents of container

AMOROLFINE 5 % GLENMARK: 2,5 mL amber glass (type I) bottle, closed with a white opaque, tamper- evident HDPE closure and a PET liner fitted inside.

Supplied with:

10 LDPE reusable applicators

12 disposable nail files

12 swabs sachets (impregnated with 70 % isopropyl alcohol in foil packs).

Pack size: One (1) bottle including 10 applicators, 12 nail files and 12 swabs packed in an outer carton.

6.6 Special precautions for disposal and other handling

No special requirements. Any unused product or waste material should be disposed of in accordance with local requirements.

7. HOLDER OF CERTIFICATE OF REGISTRATION

Glenmark Pharmaceuticals South Africa (Pty) Ltd
2nd Floor, Building D,
Stoneridge Office Park
8 Greenstone Place,
Greenstone, Edenvale,
Gauteng, 1609

8. REGISTRATION NUMBER(S)

To be allocated

9. DATE OF FIRST AUTHORISATION/ RENEWAL OF THE AUTHORISATION

To be allocated

10. DATE OF REVISION OF TEXT

To be allocated